YRK York Pharma

    RNS Number : 5580K
  York Pharma plc
  22 December 2008
   

    York Pharma plc

    ("York Pharma", "York" or "the Company")

    York Pharma announces sales collaboration with Sinclair Pharma

    22 December 2008, Milton Keynes, UK: York Pharma plc (YRK:L), the AIM-listed strategic acquirer, developer and marketer of
pharmaceutical products in the field of dermatology, announces today that it has entered into a commercial collaboration with Sinclair
Pharma in the UK. Under the terms of the agreement, each company will co-promote selected products to dermatologists and selected GP's. 

    York Pharma's sales force will co-market Sinclair's Atopiclair product for atopic dermatitis; Sinclair Pharma's sales force will
co-promote certain York Pharma products, including the anti-acne product Zindaclin and the emollient QV. The agreement comes into force in
January 2009 and relates specifically to the UK market. 

    In addition to the agreement announced today, discussions between the two companies are ongoing to evaluate the expansion of the
co-marketing relationship into other key European territories.

    Terry Sadler, Chief Executive of York Pharma, added: 

    "We're delighted to be working with Sinclair Pharma, initially in the UK market, where York has a number of approved products which can
be promoted to both GP's and dermatologists. We believe this collaboration will help optimise the value of York Pharma's portfolio and
accelerate our sales growth ahead of the anticipated commercialisation of Abasol in the UK in 2009."

    Dr Michael Flynn, CEO of Sinclair Pharma said:

     "This agreement effectively doubles the number of specialist salespersons promoting the two companies' dermatology products in the UK.
For Sinclair this is particularly important for the promotion to dermatologists of our reimbursed product Atopiclair for the treatment of
atopic dermatitis. We are exploring similar synergies with York in other European countries."

      -ends -

    About York Pharma PLC www.yorkpharma.com

    YORK PHARMA PLC is a pharmaceutical Group, established in 2003, which develops, markets and supplies branded dermatological products to
pharmaceutical wholesalers, hospitals and general practitioners within the field of dermatology. 

    The Group currently has at its disposal more than 20 patent families (with over 100 individual patents/patent applications) and
intellectual property in relation to its portfolio of novel dermatology products and technology platforms in the key therapeutic areas of
fungal infection, eczema, psoriasis, vitiligo and acne that make up more than 87% of the global $10bn dermatology market.

    About Sinclair Pharma Plc www.sinclairpharma.com 
    Sinclair Pharma plc is an international specialty pharmaceutical company.  It has a growing sales and marketing operation that is
already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries.

    Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products
and bringing them to market within a short timeframe.  Sinclair focuses on niche therapeutic areas and its current portfolio includes
products for dermatological conditions and oral health.

    For further information please contact:

 York Pharma plc                          Tel: +44 (0)870 067 2563 
 Terry Sadler, Chief Executive Officer

 Collins Stewart Europe Limited  Tel: +44 (0)207 8000 8350 
 Hugh Field
 Adam Cowen

 FinnCap           Tel: +44 (0)207 600 1658 
 Stephen Norcross

 Financial Dynamics        Tel: +44 (0)207 831 3113 
 David Yates
 Ben Brewerton
 Emma Thompson



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
AGRFGMZZZMNGRZZ

York Pharma (LSE:YRK)
Historical Stock Chart
From May 2024 to Jun 2024

York Pharma (LSE:YRK)
Historical Stock Chart
From Jun 2023 to Jun 2024